ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis

Jiahui Nie,Suying Dang,Rui Zhu,Tiantian Lu,Wei Zhang
DOI: https://doi.org/10.1186/s13058-024-01771-3
2024-01-31
Breast Cancer Research
Abstract:Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for about 20% of all breast cancer cases and is correlated with a high relapse rate and poor prognosis. ADAMTS18 is proposed as an important functional tumor suppressor gene involved in multiple malignancies, including breast cancer. It functions as an extracellular matrix (ECM) modifier. However, it remains unclear whether ADAMTS18 affects mammary tumorigenesis and malignant progression through its essential ECM regulatory function.
oncology
What problem does this paper attempt to address?